GlycoMimetics, Inc.

Pipeline Progress: Over 25 New Therapies in Development for Metastatic Liver Cancer

2 months ago

• DelveInsight's latest report reveals a robust pipeline with over 20 companies developing 25+ therapies for metastatic liver cancer, offering new hope for patients with limited treatment options. • Several promising clinical trials are underway in 2025, including studies evaluating novel combinations such as AK104 plus lenvatinib, tislelizumab with lenvatinib, and triplet therapy of nivolumab, relatlimab and bevacizumab. • Key emerging therapies include exoASO-STAT6 targeting tumor-associated macrophages, STP705 dual TGF-ß1/COX-2 inhibitor, and ONCR-177, an oncolytic viral immunotherapy expressing five transgenes to fight tumors through multiple mechanisms.

Avacta's AVA6000 Shows Promise in Targeted Cancer Therapy

5 months ago

• Avacta's pre|CISION™ platform delivers chemotherapy drugs directly to tumors, maximizing efficacy and minimizing systemic side effects. • AVA6000, a peptide drug conjugate, leverages fibroblast activation protein to release doxorubicin at the tumor site. • Phase 1 trial of AVA6000 shows favorable safety data and anti-tumor activity in salivary gland cancer and soft tissue sarcoma. • Phase 1b expansion cohorts will target triple-negative breast cancer, salivary gland cancer, and high-grade soft tissue sarcoma.

Uproleselan Shows Clinically Meaningful Improvement in Primary Refractory AML

a year ago

• GlycoMimetics' uproleselan demonstrated a significant improvement in median overall survival (mOS) for patients with primary refractory AML, with mOS reaching 31.2 months compared to 10.1 months in the placebo arm. • The Phase 3 study results indicate that uproleselan has the potential to address the unmet need for new treatment options in primary refractory AML, irrespective of backbone chemotherapy. • GlycoMimetics is planning to engage with regulators and the National Cancer Institute (NCI) to discuss potential paths forward for uproleselan in multiple AML settings. • Adverse events associated with uproleselan were consistent with the known side effect profiles of the chemotherapy regimens used in the study, supporting its safety profile.